Search Results for "quinidine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for quinidine. Results 1 to 7 of 7 total matches.
See also: Nuedexta
Dextromethorphan/Bupropion (Auvelity) for Depression
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
suppressant; it is also FDA-approved
in a fixed-dose combination with quinidine
(Nuedexta) for treatment ...
The FDA has approved an extended-release fixed-dose
combination of dextromethorphan and
bupropion (Auvelity – Axsome) for treatment of major
depressive disorder (MDD) in adults.
Table: Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters (online only)
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
Inhibitors Inducers
2D6 bupropion
cinacalcet
fluoxetine
paroxetine
quinidine
quinine
terbinafine ...
View the Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters tables
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e28-30 doi:10.58347/tml.2023.1669g | Show Introduction Hide Introduction
Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
behavioral
and psychological symptoms of dementia, including
agitation.3 Dextromethorphan/quinidine ...
The FDA has approved the oral second-generation
antipsychotic drug brexpiprazole (Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated
with dementia due to Alzheimer's disease (AD).
Brexpiprazole is the first drug to be approved in the US
for this indication. It is also approved for treatment of
schizophrenia and as an adjunct to antidepressants for
treatment of major depressive disorder.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):99-101 doi:10.58347/tml.2023.1679b | Show Introduction Hide Introduction
Drugs for Dementia
The Medical Letter on Drugs and Therapeutics • Mar 30, 2026 (Issue 1751)
DEXTROMETHORPHAN/QUINIDINE — A fixed-dose
combination of dextromethorphan, an uncompetitive
NMDA receptor ...
Alzheimer's disease (AD) is the most common cause
of dementia, but cognitive decline also occurs in
other neurological conditions, such as Parkinson's
disease, Lewy body dementia, vascular dementia, and
frontotemporal dementia.
Med Lett Drugs Ther. 2026 Mar 30;68(1751):49-56 doi:10.58347/tml.2026.1751a | Show Introduction Hide Introduction
Gepotidacin (Blujepa) — A New Antibiotic for Uncomplicated UTI
The Medical Letter on Drugs and Therapeutics • Jan 05, 2026 (Issue 1745)
by CYP3A4;
use with such drugs that have a narrow therapeutic
index (e.g., quinidine, cyclosporine) should ...
The FDA has approved gepotidacin (Blujepa – GSK), a
triazaacenaphthylene bacterial type II topoisomerase
inhibitor, for oral treatment of uncomplicated urinary
tract infections (uUTI) in female patients ≥12 years
old who weigh ≥40 kg. Gepotidacin is the first
triazaacenaphthylene antibiotic to be approved in
the US.
Med Lett Drugs Ther. 2026 Jan 5;68(1745):1-3 doi:10.58347/tml.2026.1745a | Show Introduction Hide Introduction
Two New Drugs for Gonorrhea
The Medical Letter on Drugs and Therapeutics • Mar 16, 2026 (Issue 1750)
with narrow
therapeutic indices (e.g., quinidine, cyclosporine)
should be avoided. It can also increase ...
The FDA has approved two antibiotics, gepotidacin
(Blujepa — GSK) and zoliflodacin (Nuzolvence —
Entasis), for oral treatment of uncomplicated
urogenital gonorrhea in patients ≥12 years old.
Gepotidacin is approved for use in persons weighing
≥45 kg who have limited or no alternative treatment
options; it was approved in 2025 for treatment of
uncomplicated urinary tract infection in females.
Zoliflodacin is approved for use in persons weighing
≥35 kg. Neither drug is indicated for treatment of
rectal or pharyngeal gonorrhea.
Med Lett Drugs Ther. 2026 Mar 16;68(1750):41-3 doi:10.58347/tml.2026.1750a | Show Introduction Hide Introduction
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024 (Issue 1693)
is required with coadministration of the P-gp inhibitors verapamil, amiodarone, quinidine, clarithromycin ...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 doi:10.58347/tml.2024.1693a | Show Introduction Hide Introduction
